JPH01275601A - Cellulose particle - Google Patents
Cellulose particleInfo
- Publication number
- JPH01275601A JPH01275601A JP10534688A JP10534688A JPH01275601A JP H01275601 A JPH01275601 A JP H01275601A JP 10534688 A JP10534688 A JP 10534688A JP 10534688 A JP10534688 A JP 10534688A JP H01275601 A JPH01275601 A JP H01275601A
- Authority
- JP
- Japan
- Prior art keywords
- cellulose
- particles
- average particle
- particle diameter
- adsorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 title claims abstract description 110
- 229920002678 cellulose Polymers 0.000 title claims abstract description 64
- 239000001913 cellulose Substances 0.000 title claims abstract description 63
- 238000001179 sorption measurement Methods 0.000 abstract description 19
- 229920000642 polymer Polymers 0.000 abstract description 13
- 239000002904 solvent Substances 0.000 abstract description 13
- 102000004506 Blood Proteins Human genes 0.000 abstract description 8
- 108010017384 Blood Proteins Proteins 0.000 abstract description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract description 8
- 239000003463 adsorbent Substances 0.000 abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000701 coagulant Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 238000005192 partition Methods 0.000 abstract description 5
- 229920002301 cellulose acetate Polymers 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 13
- 239000004627 regenerated cellulose Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 239000011148 porous material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000008081 blood perfusion Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920001747 Cellulose diacetate Polymers 0.000 description 2
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 229920006218 cellulose propionate Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- ALWXETURCOIGIZ-UHFFFAOYSA-N 1-nitropropylbenzene Chemical compound CCC([N+]([O-])=O)C1=CC=CC=C1 ALWXETURCOIGIZ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 101001032022 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Hydroxylamine reductase 2 Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 150000002023 dithiocarboxylic acids Chemical class 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は特定の数平均粒径を有し、粒径分布がせまく、
かつ特定の分配係数ををするセルロース系粒子に関する
。[Detailed description of the invention] [Industrial application field] The present invention has a specific number average particle size and a narrow particle size distribution.
and relates to cellulosic particles having a specific partition coefficient.
[従来の技術・発明が解決しようとする課題]セルロー
ス、再生セルロース、セルロース誘導体などのセルロー
ス系の材料は、血球成分や血漿蛋白質の非特異吸着が比
較的少ないなどの特徴を有する。それゆえ、セルロース
系の材料、とくにこれら材料で被覆された数平均粒径6
0G〜1500a+程度の活性炭粒子が、血岐中から血
漿蛋白質などを選択的に除去するために用いられている
。ただし、セルロース系粒子自体がこの目的に使用され
たことはかつてなかった。[Prior Art/Problems to be Solved by the Invention] Cellulose-based materials such as cellulose, regenerated cellulose, and cellulose derivatives have characteristics such as relatively low nonspecific adsorption of blood cell components and plasma proteins. Therefore, cellulosic materials, especially those coated with a number average particle size of 6
Activated carbon particles of about 0G to 1500a+ are used to selectively remove plasma proteins and the like from blood vessels. However, cellulosic particles themselves have never been used for this purpose.
一方、球状ポリマー粒子の製造方法として分散法とスプ
レー法が知られている。On the other hand, dispersion methods and spray methods are known as methods for producing spherical polymer particles.
分散法では、界面活性剤を含む分散媒体中に小滴状に分
散させたポリマーの希薄溶液からその溶剤を発揮させる
ことによって固化させるか(特開昭58−24480号
公報参照)、この分散液に小滴の凝固剤を徐々に加えて
固化させるかする(特開昭57−159801号公報参
照)ことによってポリマー粒子かえられる。この方法で
は広い粒径分布を有する粒子かえられる上、固化した小
滴から溶剤、分散媒体および界面活性剤を除くために水
だけでなく有機溶剤による洗浄が必要である。In the dispersion method, a dilute solution of a polymer dispersed in small droplets in a dispersion medium containing a surfactant is solidified by exerting the solvent (see Japanese Patent Application Laid-open No. 58-24480), or this dispersion is The polymer particles can be changed by gradually adding small droplets of a coagulating agent to the polymer and solidifying it (see Japanese Patent Application Laid-open No. 159801/1983). In addition to converting particles with a broad size distribution, this method requires washing with not only water but also organic solvents to remove solvent, dispersion medium, and surfactant from the solidified droplets.
スプレー法では、ポリマー溶液を凝固剤中に噴霧するこ
とによってポリマー粒子がえられる。In the spray method, polymer particles are obtained by spraying a polymer solution into a coagulant.
この粒子も広い粒径分布を持ち、また粒径も比較的大き
い(特開昭52−129788号公報参照)。These particles also have a wide particle size distribution and are relatively large in size (see Japanese Patent Laid-Open No. 129788/1983).
前記球状ポリマー粒子としてセルロース系粒子を製造し
、セルロース系材料で被覆された活性炭粒子のかわりに
用いようとしたばあい、セルロース系粒子に粒径の小さ
いものが多く含まれると、吸着効率の良好なカラム状の
吸着体として用いたばあいに圧力損失が大きくなり、溶
血などの問題が生ずる、分画分子量がシャープでなくな
るので選択性がわるくなる、などの問題が生ずる。When cellulose-based particles are produced as the spherical polymer particles and used in place of activated carbon particles coated with a cellulose-based material, adsorption efficiency may be improved if the cellulose-based particles contain many particles with small particle sizes. When used as an adsorbent in the form of a column, pressure loss increases, leading to problems such as hemolysis, and the molecular weight cut off becomes less sharp, resulting in poor selectivity.
また、セルロース系粒子に粒径の大きいものが多く含ま
れると、粒子の比表面1j1(粒子の単位体積当りの粒
子総表面積)が小さくなるので吸着速度が低下するとい
う問題が生ずる。Furthermore, if the cellulose-based particles contain many large particles, the specific surface 1j1 (total particle surface area per unit volume of particles) of the particles becomes small, resulting in a problem that the adsorption rate decreases.
[課題を解決するための手段]
本発明は前記諸問題の原因であるセルロース系粒子の粒
径分布が広いなどの問題を解消するためになされたもの
であり、数平均粒径が300〜600虜の範囲にあり、
95%以上の粒子が数平均粒径の±10%以内にあり、
分配係数が分子量10.000以下に対して063以上
、分子量100.000以上に対して0.05以下であ
るセルロース系粒子に関する。[Means for Solving the Problems] The present invention was made in order to solve the problems such as the wide particle size distribution of cellulose particles, which is the cause of the above problems, and the number average particle size is 300 to 600. It is within the captivity,
95% or more of the particles are within ±10% of the number average particle size,
The present invention relates to cellulose particles having a distribution coefficient of 063 or more for molecular weights of 10.000 or less and 0.05 or less for molecular weights of 100.000 or more.
[実施例]
本発明のセルロース系粒子は、セルロース、再生セルロ
ース、セルロース誘導体などのセルロース系の材料から
構成されている。それゆえ、該セルロース系粒子を血液
中から血漿蛋白質などを選択的に除去するなどの用途に
用いたばあいには、他の材料からの粒子を用いたばあい
と比較して血球成分や血漿蛋白質の非特異吸着が少なく
なる。また生化学物質のクロマトグラフィーによる分取
などの用途に用いたばあいにも、蛋白質の非特異吸着が
少なくなる。[Example] The cellulose-based particles of the present invention are composed of cellulose-based materials such as cellulose, regenerated cellulose, and cellulose derivatives. Therefore, when the cellulose-based particles are used for purposes such as selectively removing plasma proteins from blood, blood cell components and plasma Non-specific adsorption of proteins is reduced. Also, when used for purposes such as chromatographic separation of biochemical substances, non-specific adsorption of proteins is reduced.
前記セルロースとは、いわゆる天然セルロースのことで
あり、たとえば木綿繊維、を脱脂したもの、麻類の繊維
、木材からリグニンやヘミセルロースなどを除去してえ
られるパルプ、該バルブをさらに精製してえられる精製
セルロースなどがその代表例としてあげられるが、これ
らに限定されるものではない。The cellulose refers to so-called natural cellulose, such as pulp obtained by removing lignin and hemicellulose from defatted cotton fibers, hemp fibers, and wood, and pulp obtained by further refining the bulb. Representative examples include purified cellulose, but are not limited to these.
また前記セルロース誘導体とは、たとえばセルロースの
水酸基の一部または全部がエステル化やエーテル化など
されたもの、セルロースの水酸基の一部がエステル化さ
れ、一部がエーテル化されたものなど、セルロースから
誘導されたもののことである。The cellulose derivatives are derived from cellulose, such as those in which some or all of the hydroxyl groups of cellulose have been esterified or etherified, and those in which some of the hydroxyl groups of cellulose have been esterified and some have been etherified. It is something that has been induced.
前記セルロースの水酸基の一部または全部がエステル化
されたものの具体例としては、たとえば酢酸セルロース
、プロピオン酸セルロース、酪酸セルロース、ニトロセ
ルロース、硫酸セルロース、リン酸セルロース、酢酸酪
酸セルロース、硝酸セルロース、セルロースのジチオカ
ルボン酸エステル(ビスコースレーヨン)などがあげら
れるが、これに限定されるものではない。Specific examples of cellulose in which some or all of the hydroxyl groups have been esterified include cellulose acetate, cellulose propionate, cellulose butyrate, cellulose nitro, cellulose sulfate, cellulose phosphate, cellulose acetate butyrate, cellulose nitrate, and cellulose cellulose. Examples include, but are not limited to, dithiocarboxylic acid esters (viscose rayon).
前記セルロースの水酸基の一部または全部がエーテル化
されたものの具体例としては、たとえばメチルセルロー
ス、エチルセルロース、ベンジルセルロース、トリチル
セルロース、シアンエチルセルロース、カルボキシメチ
ルセルロース、カルボキシエチルセルロース、アミノエ
チルセルロース、オキシエチルセルロースなどがあげら
れるが、これらに限定されるものではない。Specific examples of cellulose in which some or all of the hydroxyl groups are etherified include methylcellulose, ethylcellulose, benzylcellulose, tritylcellulose, cyanethylcellulose, carboxymethylcellulose, carboxyethylcellulose, aminoethylcellulose, oxyethylcellulose, etc. , but not limited to these.
さらに前記再生セルロースとは、セルロースを一担成形
しやすいセルロース誘導体にして成形したのち、加水分
解などによりセルロースを再生させたセルロースのこと
である。Furthermore, the regenerated cellulose refers to cellulose obtained by molding cellulose into a cellulose derivative that can be easily molded in one piece, and then regenerating the cellulose by hydrolysis or the like.
前記セルロース系粒子を構成するセルロース系材料のう
ちでは、精製セルロースが不純物が少なく、溶解したと
き未溶解物が少ないなどの点から好ましく、酢酸セルロ
ース、プロピオン酸セルロースなどのセルロースエステ
ルが、多種の溶剤に溶解するため、粒子製造時の種々の
製造条件の選択範囲も広くなり、粒子の分配係数やスキ
ン層の厚さ、内部の網目状組織における孔の大きさなど
の調整が容易となり、所望のセルロース系粒子を製造し
うるなどという点から好ましく、さらに加水分解するこ
とによって容易に再生セルロース粒子にすることもでき
るという点から一層好ましい。Among the cellulose-based materials constituting the cellulose-based particles, purified cellulose is preferable because it has fewer impurities and leaves less undissolved matter when dissolved, and cellulose esters such as cellulose acetate and cellulose propionate are preferable when used in various solvents. As a result, the range of selection of various manufacturing conditions during particle production is widened, and it is easy to adjust the particle distribution coefficient, skin layer thickness, pore size in the internal network structure, etc. to achieve the desired result. This is preferable because cellulose-based particles can be produced, and it is even more preferable because it can be easily converted into regenerated cellulose particles by hydrolysis.
本発明のセルロース系粒子は、球状(はぼ真球のものの
みならず、短径/長径が0.8程度までの楕円状のもの
の回転体などをも含む概念である)の粒子であり、数平
均粒径(楕円状回転体のばあいには体積平均粒径、すな
わち長径の2乗に短径を乗じた値の3乗根として求める
)が300〜eoo Jlの範囲にあり、95%以上の
粒子が数平均粒径の±10%以内にあり、かつ分配係数
が分子m to、ooo以下に対して0.3以上、分子
1too、ooo以上に対して0.05以下である。こ
のようなセルロース系粒子の表面には、通常10虜以下
の厚さのスキン層が存在し、内部は0.1〜10−の孔
を有する網目状組織からなっている。The cellulose-based particles of the present invention are spherical particles (a concept that includes not only spherical particles but also elliptical bodies of rotation with a minor axis/long axis of up to about 0.8), The number average particle diameter (in the case of an elliptical rotating body, the volume average particle diameter, that is, determined as the cube root of the value obtained by multiplying the square of the major axis by the minor axis) is in the range of 300 to eoo Jl, and 95% The above particles are within ±10% of the number average particle diameter, and the distribution coefficient is 0.3 or more for molecules m to, ooo or less, and 0.05 or less for molecules 1 too, ooo or more. On the surface of such cellulose-based particles, there is usually a skin layer with a thickness of 10 pores or less, and the inside consists of a network structure having pores of 0.1 to 10 pores.
また粒子の空孔率は50〜95%程度である。Further, the porosity of the particles is about 50 to 95%.
第1図および第2図は本発明のセルロース系粒子のスキ
ン層(第1図の上端左から約1/3の部分から左端上か
ら約1/2の部分にかけて斜に存在する白っぽい層のう
ちの表面部分)およびその内側の網目状構造を観察した
電子顕微鏡写真(15,000倍)の例である。Figures 1 and 2 show the skin layer of the cellulose-based particles of the present invention (the whitish layer that exists diagonally from about 1/3 from the upper left to about 1/2 from the upper left in Figure 1). This is an example of an electron micrograph (15,000x magnification) observing the surface portion of
前記数平均粒径がBoo −未満になると、血液中から
血漿蛋白質を選択的に除くための吸着体用のセルロース
系粒子として、とくにアルブミン(分子!58.000
)より小さい分子量の血漿蛋白質を直接血液潅流法によ
って吸着除去するための吸着材として使用したばあいの
圧力損失が大きくなり、溶血がおこりやすくなるなどの
問題が生じやすくなる。また600umをこえると比表
面積が小さくなり、吸着速度が小さくなるので、血液の
循環量の割に不要物の吸着除去量が少なくなる。When the number average particle diameter is less than Boo -, especially albumin (molecular! 58,000
) When used as an adsorbent for adsorbing and removing plasma proteins with smaller molecular weights by direct blood perfusion, the pressure loss increases and problems such as hemolysis are more likely to occur. Further, when the thickness exceeds 600 um, the specific surface area becomes small and the adsorption speed becomes low, so that the amount of adsorption and removal of unnecessary substances becomes small in relation to the amount of blood circulation.
また、数平均粒径の±10%以内の粒子の割合が95%
未満しかないばあいには、前記のごとき吸着体用の吸着
材として使用したばあいに圧力損失が大きくなったり、
溶血がおこりやすくなったりしやすくなる。In addition, the proportion of particles within ±10% of the number average particle diameter is 95%.
If the amount is less than
Hemolysis may occur more easily.
さらに、分配係数が分子QI0.000以下に対して0
.3以上、分子量100,000以上に対して0.05
以下の範囲をはずれるばあいには、前記のごとき吸着体
用の吸着材として使用したばあいの選択性が低下し、ア
ルブミン以上の分子量のものも吸着されやすくなったり
、逆に著しく吸着速度が小さくなり、不要物の吸着除去
が充分行なわれなくなるなどの問題が生じやすくなる。Furthermore, the distribution coefficient is 0 for molecular QIs below 0.000.
.. 3 or more, 0.05 for molecular weight 100,000 or more
If the following range is exceeded, the selectivity when used as an adsorbent for the adsorbent described above will decrease, and substances with molecular weights higher than albumin will be easily adsorbed, or conversely, the adsorption rate will be significantly reduced. This tends to cause problems such as insufficient adsorption and removal of unnecessary substances.
なおセルロース系粒子内部の網目状組織の網目の大きさ
が0.1ρ未満になると、吸着体用の吸着材として用い
たばあいに血液中の前記不要物の吸着速度が小さくなる
のみならず、これら不要物の吸着除去が充分行なわれな
くなるなどの傾向が生じる。また10項をこえると機械
的強度が充分でなくなり、カラムへの充填時や輸送時な
どに粒子が変形したり、破砕されたりしやすくなる傾向
が生じ、またこのような変形が発生したばあいには圧力
損失が増大したり、微小な破片が血液中に混入する傾向
が生じる。Note that if the size of the network structure inside the cellulose particles is less than 0.1ρ, when used as an adsorbent for an adsorbent, not only will the rate of adsorption of the unnecessary substances in the blood decrease, There is a tendency that these unnecessary substances are not adsorbed and removed sufficiently. In addition, if the value exceeds 10, the mechanical strength will not be sufficient, and the particles will tend to be easily deformed or crushed during filling into columns or transportation, and if such deformation occurs, This results in increased pressure loss and a tendency for microscopic debris to enter the blood.
つぎに本発明のセルロース系粒子の製法にっいて説明す
る。Next, the method for producing cellulose particles of the present invention will be explained.
本発明のセルロース系粒子は、セルロース、セルロース
誘導体などを溶解させたポリマー溶液を、たとえば特開
昭82−1910H号公報に記載の装置および方法(振
動法と乾湿式凝固法とを組合わせた方法)を適用するこ
とにより製造されうる。The cellulose-based particles of the present invention can be obtained by dissolving a polymer solution in which cellulose, cellulose derivatives, etc. ) can be manufactured by applying.
前記ポリマー溶液を調製する際に用いる溶剤としては、
セルロースの溶剤となる、たとえば銅アンモニア水溶液
、ジメチルスルホキシドとホルムアミドとの混合液、チ
オシアン酸カルシウム水溶液など、また代表的なセルロ
ース誘導体である酢酸セルロースの溶剤となる、たとえ
ばジメチルスルホキシド、ジメチルホルムアミド、ジメ
チルアセトアミド、N−メチル−2−ピロリドン、アセ
トンなどがあげられる。The solvent used when preparing the polymer solution is
Solvents for cellulose, such as an aqueous cuprammonium solution, a mixture of dimethyl sulfoxide and formamide, and an aqueous calcium thiocyanate solution; and solvents for cellulose acetate, a typical cellulose derivative, such as dimethyl sulfoxide, dimethyl formamide, and dimethyl acetamide. , N-methyl-2-pyrrolidone, acetone, and the like.
これらの溶剤には、えられるセルロース系粒子のスキン
層の厚さや内部の網目状組織の孔の大きさを調節して分
配係数などを調節するために、メタノール、エタノール
、エチレングリコ−ル、プロピレングリコール、グリセ
リン、水、無機塩類、ポリエチレングリコール、ポリビ
ニルピロリドンなどを加えてもよい。These solvents include methanol, ethanol, ethylene glycol, and propylene in order to adjust the thickness of the skin layer and the size of the pores in the internal network structure of the resulting cellulose particles to adjust the distribution coefficient. Glycol, glycerin, water, inorganic salts, polyethylene glycol, polyvinylpyrrolidone, etc. may also be added.
このようにして調製されたポリマー溶液は、たとえば特
開昭82−191038号公報に記載のごとき装置を用
いて均一な小滴として気相中に噴出せしめられ、はぼ球
形になる飛行距離以上を飛行せしめられたのち凝固剤と
接触せしめられる。The polymer solution prepared in this way is ejected into the gas phase as uniform droplets using a device such as that described in Japanese Patent Application Laid-Open No. 82-191038, and is ejected into a gas phase over a flying distance to form a spherical shape. After being flown, it is brought into contact with a coagulant.
このようにして製造されるセルロース系粒子はほぼ真球
の粒子である。The cellulose-based particles produced in this manner are approximately perfectly spherical particles.
前記凝固剤はポリマーの非溶剤からなるが、小滴を構成
する溶剤と溶けあい、小滴が自然にぬれるような表面張
力を有するものが好ましい。The coagulant is made of a polymeric non-solvent, and preferably has a surface tension such that it dissolves in the solvent constituting the droplets and naturally wets the droplets.
このような凝固剤の具体例として、たとえば水、水と前
記良溶剤あるいは非溶剤との混合液、水と界面活性剤と
の混合液などがあげられる。Specific examples of such coagulants include water, a mixture of water and the aforementioned good solvent or non-solvent, and a mixture of water and a surfactant.
一般にポリマー溶液中のポリマーの濃度が高く、非溶剤
の割合が少なく、水のように凝固力の強い凝固液を使用
するとスキン層の孔が小さくなる(分配係数が小さくな
る)。Generally, when the concentration of the polymer in the polymer solution is high, the proportion of non-solvent is low, and a coagulating liquid with strong coagulating power, such as water, is used, the pores of the skin layer become smaller (the distribution coefficient becomes smaller).
このようにしてえられた本発明のセルロース系粒子は特
定の平均粒径および特定の粒径分布を有し、かつ特定の
分配係数を有するため、クロマトグラフ用充填材、酵素
固定用担体、アフィニティクロマトグラフィー用担体、
直接血液潅流用の吸着体などの用途に使用することがで
き、これらの用途に使用したばあいには圧力損失、選択
性、吸着速度などの点で優れたものとなる。The cellulose-based particles of the present invention obtained in this way have a specific average particle size, a specific particle size distribution, and a specific distribution coefficient, so they can be used as fillers for chromatography, as carriers for enzyme immobilization, and as affinity particles. chromatography carrier,
It can be used as an adsorbent for direct blood perfusion, and when used in these applications, it is excellent in terms of pressure drop, selectivity, adsorption rate, etc.
つぎに本発明のセルロース系粒子を実施例に基づき説明
するが、本発明がこれら実施例に限定されないことは勿
論である。Next, the cellulose particles of the present invention will be explained based on Examples, but it goes without saying that the present invention is not limited to these Examples.
実施例に
酢酸セルロースを濃度が12.5%(重量%、以下同様
)となるようにジメチルスルホキシド/プロピレングリ
コールが重量比で476の混合液に溶解させた。In an example, cellulose acetate was dissolved in a mixed solution of dimethyl sulfoxide/propylene glycol in a weight ratio of 476 so that the concentration was 12.5% (weight %, the same applies hereinafter).
ノズルの前方5mmのところに2011の間隔を離して
、巾5aa、液滴の進行方向の長さ25備の大きさの平
行平板状の電極を設置し、該電極とノズルとの間に80
0■の直流電圧を印加した。このノズルに設けた直径2
50−のオリフィスから、145℃に保持した前記溶液
を7.8m/secの線速で385011zの振動を加
えながら吐出させ、該溶液の均一な液滴を形成させ、空
気中を約31飛行させたのち、23℃の10%メタノー
ル水溶液中へ侵入させて凝固させ、二酢酸セルロースの
粒子をえた。Parallel plate-like electrodes with a width of 5 aa and a length of 25 mm in the direction of droplet travel are installed at a distance of 2011 mm in front of the nozzle, and a parallel plate electrode with a width of 5 aa and a length of 25 mm in the direction of droplet travel is installed between the electrode and the nozzle.
A DC voltage of 0.0 cm was applied. Diameter 2 provided on this nozzle
The solution maintained at 145° C. was discharged from the 50° orifice at a linear velocity of 7.8 m/sec while applying vibration of 385011z to form uniform droplets of the solution, which were flown through the air for about 31°. Thereafter, the particles were solidified by entering a 10% aqueous methanol solution at 23° C. to obtain particles of cellulose diacetate.
えられた二酢酸セルロース粒子を50℃、0.8%の力
性ソーダ水溶液に投入して、2時間撹拌したのち回収し
、中和番水洗して、はぼ100%再生された再生セルロ
ース粒子をえた。The obtained cellulose diacetate particles were put into a 0.8% aqueous sodium hydroxide solution at 50°C, stirred for 2 hours, recovered, neutralized and washed with water to obtain 100% regenerated cellulose particles. I got it.
えられた再生セルロース粒子の数平均粒径を下記方法に
より測定したところ、430ρで、粒子がすべて数平均
粒径±5%以内にあった。The number average particle size of the obtained regenerated cellulose particles was measured by the following method, and found to be 430ρ, which was within ±5% of the number average particle size.
えられた再生セルロース粒子内の液体をエタノールで置
換してから炭酸ガス臨界点乾燥(■日立製作所要の臨界
点乾燥器HCP−2を使用)させ、金を蒸着させたのち
走査型電子顕微鏡で観察したところ、第1図に示すよう
に表面に厚さ約0.2−のスキン層(上端左から約17
3の部分から左端上から約1/2の部分にかけて斜に存
在する白っぽい層のうちの表面部分)があり、第2図に
示すように内部は孔径が約0.2〜2虜の多孔質網目状
組織であった。After replacing the liquid in the obtained regenerated cellulose particles with ethanol, they were subjected to critical point drying with carbon dioxide gas (using Hitachi's critical point dryer HCP-2), gold was evaporated, and then they were dried using a scanning electron microscope. Upon observation, as shown in Figure 1, a skin layer with a thickness of about 0.2 -
From part 3 to about 1/2 of the way from the top of the left end, there is a whitish layer (the surface part) that exists diagonally, and as shown in Figure 2, the inside is porous with a pore size of about 0.2 to 2 mm. It had a mesh-like structure.
分子tito、ooo、110.000のデキストラン
に対する該粒子の分配係数を下記方法により測定したと
ころ、それぞれ0.67および0であった。The partition coefficients of the particles for dextran of molecules tito, ooo, and 110.000 were measured by the following method and were 0.67 and 0, respectively.
前記再生セルロース粒子を内径1411%長さ7(至)
のカラムに充填し、ヘパリンを30ユニット/ml加え
た牛の新鮮面を37℃に保温して流し、徐々に流量を大
きくして圧力損失を測定したところ、線速の増加と共に
ほぼ直線的に圧力損失が大きくなったが、gc+e/m
1nのときでも50mm11gで、そのまま1時間連続
運転してもこの値はほとんど変わらず、直接血液潅流可
能であった。The regenerated cellulose particles have an inner diameter of 1411% and a length of 7 (to)
When we filled a column with 30 units/ml of heparin and poured a fresh cow's surface while keeping it at 37℃, we gradually increased the flow rate and measured the pressure drop.As the linear velocity increased, the pressure drop was almost linear. Although the pressure loss increased, gc+e/m
Even when it was 1n, it was 50mm and 11g, and even if it was operated continuously for 1 hour, this value hardly changed, and direct blood perfusion was possible.
前記再生セルロース粒子をエピクロルヒドリンと反応さ
せ、ついでn−ヘキシルアミンと反応させて、n−ヘキ
シルアミン固定化セルロース粒子をえた。この粒子の選
択性を下記方法により測定したところ、リゾチーム、ア
ルブミンに対する吸着率はそれぞれ7396および8%
であった。The regenerated cellulose particles were reacted with epichlorohydrin and then with n-hexylamine to obtain n-hexylamine-immobilized cellulose particles. When the selectivity of these particles was measured using the method below, the adsorption rates for lysozyme and albumin were 7396% and 8%, respectively.
Met.
(数平均粒径および粒径分布)
数百側(約500〜1000個)の粒子の光学顕微鏡像
を画像処理装置(■ニレコ製のルーゼツクス■)を使用
して処理して求める。(Number average particle size and particle size distribution) Optical microscopic images of hundreds of particles (approximately 500 to 1000 particles) are processed using an image processing device (Ruzetx, manufactured by Nireco).
(分配係数(Kav) )
種々の分子量のデキストランおよびプルランの水溶液を
用いて分配クロマトグラフィーを行ない、溶出曲線を求
めて式:
%式%
(式中、Voは分子量2,000.000のデキストラ
ンの溶出曲線のピーク位置に相当する溶出液量、Vtは
カラム体積、veは試料の溶出曲線のピーク位置に相当
する溶出液ti)から求める。(Partition coefficient (Kav)) Partition chromatography was performed using aqueous solutions of dextran and pullulan with various molecular weights, and the elution curve was determined using the formula: The amount of eluate corresponding to the peak position of the elution curve, Vt is the column volume, and ve is determined from the eluate ti) corresponding to the peak position of the sample elution curve.
(選択性)
1)H7,4に調整した0、025Mリン酸緩衝液にリ
ゾチームおよびアルブミンをそれぞれ3 tsg/ m
lおよび7.3mg/mlの濃度になるように溶解させ
た各々の液6容量に対し、沈降体積として1容量の割合
になるようにに血漿蛋白質に吸着性を有するリガンドを
固定したセルロース系粒子を加え、37℃で2時間振温
したのち、上澄液の濃度を測定してそれぞれの吸着率を
求める。(Selectivity) 1) Lysozyme and albumin were each added at 3 tsg/m in 0.025M phosphate buffer adjusted to H7.4.
Cellulose-based particles on which a ligand adsorbable to plasma proteins is immobilized so that the sedimentation volume is 1 volume per 6 volumes of each solution dissolved at a concentration of 1 and 7.3 mg/ml. After shaking at 37°C for 2 hours, the concentration of the supernatant was measured to determine the adsorption rate of each.
原液濃度−上澄液濃度
吸着率(%)−X100
原液濃度
(直接血液潅流の可能性の判断)
ヘパリンを30ユニツト/ ml加えた牛の新鮮面を3
7℃に保温して、粒子を充填した長さ7〔、内径14m
5φのカラムに徐々に流量を増加させながら線速度が8
cm/sinになるまで流して、この間に圧力損失が1
100ail1をこえないものを直接血液潅流が可能で
あると判断した。Stock solution concentration - Supernatant solution concentration Adsorption rate (%) - X100 Stock solution concentration (judgment of possibility of direct blood perfusion) Fresh side of cow with 30 units/ml of heparin added
Insulated at 7℃ and filled with particles, length 7〔, inner diameter 14m.
The linear velocity was set to 8 while gradually increasing the flow rate to the 5φ column.
cm/sin, and during this time the pressure loss is 1
It was judged that direct blood perfusion was possible if the number did not exceed 100 ail1.
比較例1
数平均粒径が450遍で、89%の粒子が数平均粒径の
±10%以内にある市販の再生セルロース粒子を用いて
実施例1と同様にして圧力損失を測定したところ、線速
が2cm/slnですでに圧力損失が1100avlr
をこえ、そののちさらに圧力損失が大きくなったので実
験を中止した。Comparative Example 1 Pressure drop was measured in the same manner as in Example 1 using commercially available regenerated cellulose particles with a number average particle size of 450 and 89% of particles within ±10% of the number average particle size. Linear speed is 2cm/sln and pressure loss is already 1100avlr
After that, the pressure loss became even larger, so the experiment was stopped.
比較例2
均一な液滴の形成条件を変更して実施例1と同様にして
数平均粒径が270虜で100%の粒子が数平均粒径の
±5%以内にある再生セルロース粒子をえた。この粒子
を用いて実施例1と同様にして圧力損失を測定したとこ
ろ、線速が5cm/sinのところで100a+a+H
gをこえた。Comparative Example 2 Regenerated cellulose particles with a number average particle size of 270 particles and 100% of particles within ±5% of the number average particle size were obtained in the same manner as in Example 1 by changing the conditions for forming uniform droplets. . When the pressure drop was measured using these particles in the same manner as in Example 1, it was found that the pressure drop was 100a+a+H at a linear velocity of 5 cm/sin.
It exceeded g.
比較例3
分子量ILQ、QOQのデキストランに対する分配係数
が0.3の市販の再生セルロース粒子に実施例1のばあ
いと同様にしてn−ヘキシルアミンを固定化してリゾチ
ームとアルブミンとの吸着率を測定したところ、それぞ
れ24%および58%であった。Comparative Example 3 In the same manner as in Example 1, n-hexylamine was immobilized on commercially available regenerated cellulose particles having molecular weights ILQ and QOQ and a distribution coefficient of 0.3 for dextran, and the adsorption rate of lysozyme and albumin was measured. The results were 24% and 58%, respectively.
[発明の効果]
本発明のセルロース系粒子は特定の数平均粒径および特
定の粒径分布を有し、かつ特定の分配係数を有するため
、血液中から血漿蛋白質を選択的に除くための吸着体用
のセルロース系粒子、とくにアルブミンより小さい分子
量の血漿蛋白質を直接血液潅流法によって吸着除去する
などの用途に用いたばあいには、圧力損失が小さく、溶
血などの問題が生じにくくなる、選択性も向上し、吸着
量も多くなるなどの効果が達成される。[Effects of the Invention] Since the cellulose-based particles of the present invention have a specific number average particle size, a specific particle size distribution, and a specific distribution coefficient, they can be used for adsorption to selectively remove plasma proteins from blood. Cellulose-based particles for body use, especially when used for purposes such as adsorption and removal of plasma proteins with a molecular weight smaller than albumin, by direct blood perfusion, are selected because pressure loss is small and problems such as hemolysis are less likely to occur. Effects such as improved properties and increased adsorption amount are achieved.
第1図は本発明のセルロース系粒子の構造を説明するた
めの写真であり、粒子断面の表面付近(表面のスキン層
およびその内側の網目状構造)を15000倍に拡大し
た写真、第2図は実施例1でえられた本発明のセルロー
ス系粒子の内部構造を説明するための写真であり、粒子
断面を15000倍に拡大した写真である。
第1 図
手続補正書印釦
ニ
日
特許庁長官 吉田文毅 殿 1
1事件の表示
昭和63年特許願第105346号
2発明の名称
セルロース系粒子
3補正をする者
事件との関係 特許出願人
住 所 大阪市北区中之島三丁目2番4号名 称
(094)鐘淵化学工業株式会社代表者新納眞人
宗子
2−こ
ε停
名
5補正の対象
(1)明細書の「発明の詳細な説明」の欄5補正の内容
(1)明細書2頁12行の「発揮」を「揮発」と補正す
る。
(2)同6頁14行の「未溶解物」を「非溶解物」と補
正する。
(3)同8頁8行のr5g、000Jをr67.000
〜68.0OOJと補正する。
(4) 同10頁11行の「ホルムアミド」を「パラ
ホルムアルデヒド」と補正する。
(5)同1B頁5行の「振温」を「振盪」と補正する。
以 上Figure 1 is a photograph for explaining the structure of the cellulose-based particles of the present invention, and is a photograph showing the vicinity of the surface of the particle cross section (the skin layer on the surface and the network structure inside thereof) magnified 15,000 times. is a photograph for explaining the internal structure of the cellulose-based particles of the present invention obtained in Example 1, and is a photograph in which the cross section of the particles is enlarged 15,000 times. Figure 1 Procedural amendment stamp button 1
1 Description of the case Patent Application No. 105346 filed in 1988 2 Name of the invention Cellulose-based particles 3 Person making the amendment Relationship to the case Patent applicant Address 3-2-4 Nakanoshima, Kita-ku, Osaka Name Name
(094) Kanebuchi Chemical Industry Co., Ltd. Representative Masato Niino 2-Ko ε Name 5 Subject of amendment (1) Contents of amendment to column 5 of “Detailed explanation of the invention” of the specification (1) Page 2 of the specification Correct "exhibit" in line 12 to "volatize". (2) "Undissolved matter" on page 6, line 14 is corrected to "undissolved matter." (3) r5g, 000J on page 8, line 8, r67.000
Corrected to ~68.0OOJ. (4) "Formamide" on page 10, line 11 is corrected to "paraformaldehyde." (5) Correct "shaking temperature" in line 5 of page 1B to "shaking". that's all
Claims (1)
5%以上の粒子が数平均粒径の±10%以内にあり、分
配係数が分子量10,000以下に対して0.3以上、
分子量100,000以上に対して0.05以下である
セルロース系粒子。1 The number average particle size is in the range of 300 to 600 μm, and 9
5% or more of the particles are within ±10% of the number average particle diameter, and the distribution coefficient is 0.3 or more for a molecular weight of 10,000 or less,
Cellulose particles having a molecular weight of 0.05 or less with respect to a molecular weight of 100,000 or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10534688A JPH01275601A (en) | 1988-04-27 | 1988-04-27 | Cellulose particle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10534688A JPH01275601A (en) | 1988-04-27 | 1988-04-27 | Cellulose particle |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01275601A true JPH01275601A (en) | 1989-11-06 |
JPH0587081B2 JPH0587081B2 (en) | 1993-12-15 |
Family
ID=14405174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10534688A Granted JPH01275601A (en) | 1988-04-27 | 1988-04-27 | Cellulose particle |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01275601A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0955332A1 (en) * | 1997-01-07 | 1999-11-10 | Kaneka Corporation | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
WO2006009179A1 (en) * | 2004-07-23 | 2006-01-26 | Kaneka Corporation | Direct hemoperfusion adsorber packed with adsorbent having water insoluble microparticle removed therefrom, and method of obtaining direct hemoperfusion adsorbent having water insoluble microparticle removed therefrom |
WO2006093205A1 (en) * | 2005-03-03 | 2006-09-08 | Kaneka Corporation | Method and device for cell preparation |
JP2013010701A (en) * | 2011-06-28 | 2013-01-17 | Jnc Corp | Endotoxin adsorbent,column for whole blood perfusion type extracorporeal circulation using the same, and chromatography filler for purifying pharmaceutical drug |
WO2014129382A1 (en) * | 2013-02-25 | 2014-08-28 | テルモ株式会社 | Polysaccharide powder and anti-adhesion material containing same |
WO2017073626A1 (en) * | 2015-10-30 | 2017-05-04 | 東レ株式会社 | Cellulose ether derivative fine particles |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5757556A (en) * | 1980-09-25 | 1982-04-06 | Asahi Chemical Ind | Blood purifying method and apparatus |
JPS62191033A (en) * | 1986-02-06 | 1987-08-21 | Kanegafuchi Chem Ind Co Ltd | Method for forming uniform liquid droplet |
-
1988
- 1988-04-27 JP JP10534688A patent/JPH01275601A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5757556A (en) * | 1980-09-25 | 1982-04-06 | Asahi Chemical Ind | Blood purifying method and apparatus |
JPS62191033A (en) * | 1986-02-06 | 1987-08-21 | Kanegafuchi Chem Ind Co Ltd | Method for forming uniform liquid droplet |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0955332A4 (en) * | 1997-01-07 | 2000-05-24 | Kaneka Corp | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
US6599620B2 (en) | 1997-01-07 | 2003-07-29 | Kaneka Corporation | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
EP1693402A2 (en) * | 1997-01-07 | 2006-08-23 | Kaneka Corporation | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
EP1693402A3 (en) * | 1997-01-07 | 2009-05-27 | Kaneka Corporation | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
US7763348B2 (en) | 1997-01-07 | 2010-07-27 | Kaneka Corporation | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
EP0955332A1 (en) * | 1997-01-07 | 1999-11-10 | Kaneka Corporation | Cellulosic particles, spherical object comprising cross-linked polymer particles, and adsorbent for body fluid purification |
US8272518B2 (en) | 2004-07-23 | 2012-09-25 | Kaneka Corporation | Direct hemoperfusion adsorber packed with adsorbent having water insoluble microparticle removed therefrom, and method of obtaining direct hemoperfusion adsorbent having water insoluble microparticle removed therefrom |
WO2006009179A1 (en) * | 2004-07-23 | 2006-01-26 | Kaneka Corporation | Direct hemoperfusion adsorber packed with adsorbent having water insoluble microparticle removed therefrom, and method of obtaining direct hemoperfusion adsorbent having water insoluble microparticle removed therefrom |
KR101236046B1 (en) * | 2004-07-23 | 2013-02-21 | 카네카 코포레이션 | Direct hemoperfusion adsorber packed with adsorbent having water insoluble microparticle removed therefrom, and method of obtaining direct hemoperfusion adsorbent having water insoluble microparticle removed therefrom |
JPWO2006009179A1 (en) * | 2004-07-23 | 2008-05-01 | 株式会社カネカ | Adsorber for direct blood perfusion filled with adsorbent from which water-insoluble fine particles have been removed, and method for obtaining adsorbent for direct blood perfusion from which water-insoluble fine particles have been removed |
JP4908216B2 (en) * | 2004-07-23 | 2012-04-04 | 株式会社カネカ | Adsorber for direct blood perfusion filled with adsorbent from which water-insoluble fine particles have been removed, and method for obtaining adsorbent for direct blood perfusion from which water-insoluble fine particles have been removed |
JP4949230B2 (en) * | 2005-03-03 | 2012-06-06 | 株式会社カネカ | Cell preparation method and apparatus |
WO2006093205A1 (en) * | 2005-03-03 | 2006-09-08 | Kaneka Corporation | Method and device for cell preparation |
JP2013010701A (en) * | 2011-06-28 | 2013-01-17 | Jnc Corp | Endotoxin adsorbent,column for whole blood perfusion type extracorporeal circulation using the same, and chromatography filler for purifying pharmaceutical drug |
WO2014129382A1 (en) * | 2013-02-25 | 2014-08-28 | テルモ株式会社 | Polysaccharide powder and anti-adhesion material containing same |
EP2960254A4 (en) * | 2013-02-25 | 2016-10-26 | Terumo Corp | Polysaccharide powder and anti-adhesion material containing same |
US9738730B2 (en) | 2013-02-25 | 2017-08-22 | Terumo Kabushiki Kaisha | Polysaccharide powder and anti-adhesive material containing the same |
WO2017073626A1 (en) * | 2015-10-30 | 2017-05-04 | 東レ株式会社 | Cellulose ether derivative fine particles |
JPWO2017073626A1 (en) * | 2015-10-30 | 2017-11-30 | 東レ株式会社 | Ether type cellulose derivative fine particles |
CN108350091A (en) * | 2015-10-30 | 2018-07-31 | 东丽株式会社 | Ether series fiber element derivative particle |
Also Published As
Publication number | Publication date |
---|---|
JPH0587081B2 (en) | 1993-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5993661A (en) | Macroporous or microporous filtration membrane, method of preparation and use | |
US7935418B2 (en) | Functional porous fibres | |
US4840733A (en) | Fine porous membrane and process for producing the same | |
JP7270993B2 (en) | Structurally controllable ion-exchange nanofiber skeleton three-dimensional separation material and its manufacturing method | |
US4983304A (en) | Membrane for separation of water-alcohol mixed liquid and process for preparation thereof | |
JPS62176508A (en) | Surface modification of predetermined polymeric support material | |
SE452161B (en) | PROCEDURE FOR THE PREPARATION OF POROSA CELLULOSAPERLOR AND ITS USE | |
US20220025131A1 (en) | Method for producing cellulose beads | |
JPH04277021A (en) | Surface denatured supporting membrane and method for denaturing surface of supporting membrane | |
JPS6214642B2 (en) | ||
JP6742302B2 (en) | Method for producing porous cellulose medium | |
JPH01275601A (en) | Cellulose particle | |
US5387345A (en) | Cellulose acetate membranes | |
CN115569521A (en) | Cellulose composite ultrafiltration membrane and preparation method thereof | |
EP3549623B1 (en) | Use of a blood component selective adsorption filtering medium and blood filter | |
JPH01278534A (en) | Bimodal particle | |
JPH0631145A (en) | Dialyzer consisting of cellulose acetate or cellulose acetate derivative and having interior through space as in form of hollow fiber and its production | |
JPH01277570A (en) | Beta2-microglobulin adsorbent for extracorporeal circulation treatment | |
JPS63287503A (en) | Polyamide microporous membrane with fixed chitosan | |
JPH01275641A (en) | Polymer particle | |
JP3941980B2 (en) | Cellulosic carrier and method for producing the same | |
JPS6057882B2 (en) | Separation support | |
KR20240063812A (en) | Porous particles, manufacturing method thereof, and filler for chromatography using the same | |
JPS63246657A (en) | Gel chromatography column | |
JP2883406B2 (en) | Hydrophilic membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |